A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach
<b>Background/Objective:</b> Sacubitril/Valsartan are a combination drug approved for heart failure treatment, known to enhance natriuretic peptide activity and inhibit the renin–angiotensin–aldosterone system (RAAS). While its clinical efficacy is well-established, its broader impact on human metab...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2025-08-01
|
| シリーズ: | Pharmaceuticals |
| 主題: | |
| オンライン・アクセス: | https://www.mdpi.com/1424-8247/18/9/1264 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
